Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT01647971 · COMPLETED

Trial details

NCT number: NCT01647971
Sponsor: TG Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Hodgkins Lymphoma B-cell Lymphoma Waldenstrom's Macroglobulinemia Marginal Zone Lymphoma Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Primary Central Nervous System Lymphoma

Start date: 2012-07-19
Primary completion: 2015-05-01
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.